Figure 4.

Effects of exogenous T-cell cytokine receptor (TCCR) on human umbilical vein endothelial cells (HUVECs). A: After HUVECs were treated with recombinant human TCCR/WSX-1/Fc chimera protein for 8 h, tube formation was detected with phase contrast microscopy. Twenty percent fetal bovine serum (FBS) was used as a control. B: The number of tubes was quantified by counting the total tubes per five fields in a blinded manner. C: western blot using antibody against ERK, phosphorylated extracellular signal-regulated kinase (ERK), and β-actin from HUVECs that were treated with 100 pM recombinant TCCR or control IgG for the indicated times.